Pharmalot… Pharmalittle… The Weekend Nears
Make a commentBy Ed Silverman // January 27th, 2012 // 8:18 am
And so, yet another working week will soon draw to a close. As you know, this gives us permission to daydream about weekend plans. We have a very modest agenda, though. A little exercise, a few naps and catching up on some reading. And you? Anything interesting planned? Perhaps, this is an opportunity to spend a few moments with someone special or tidy up around your lily pad. Or as the Republican primary has reminded us, the time is nearly at hand to ready your taxes. Whatever you do, have a grand time, but be safe. See you soon…
European Parliament Rapporteur Quits In ACTA Protest (BBC)
EU Ends Procedural Case Into Servier (Bloomberg News)
Why Biogen Got Out Of Corporate Venture Capital (Xconomy)
Ranbaxy Gives Up 180-Day Exclusivity On Which Drugs? (Bloomberg News)
J&J Wins Trial Over Levaquin Side Effects (Bloomberg News)
Active Ingredient In Viagra Shrunk Disfiguring Growth In Kids (HealthDay)
Pakistan Probes State Officials And Pharma Contracts Over Deaths (The Nation)
Merck Urges Thailand To Direct Scientists Into R&D (Bangkok Post)
Amgen Misses Profit Estimates On Plunging Anemia Med Sales (Bloomberg News)
Bristol-Myers Profits Fall Short Of Wall Street Forecasts (Associated Press)
EDITOR’S NOTE: Please check this post for updates throughout the morning
pic thx to morristownnps on flickr
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
ACTA, Amgen, Biogen Idec, Bristol Myers Squibb, European Parliament, Generics, JJ, Johnson & Johnson, Levaquin, Merck, Pakistan, Ranbaxy Laboratories, Thailand, Venture Capital, Viagra